Regeneron's Chief Executive Officer and Chief Scientific Officer named
"Management Team of the Year" by Scrip Intelligence
TARRYTOWN, N.Y., Nov. 25, 2013
TARRYTOWN, N.Y., Nov. 25, 2013 /PRNewswire/ --Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that Leonard S. Schleifer, M.D., Ph.D.,
President, and Chief Executive Officer of Regeneron, and George D.
Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President
of Regeneron Laboratories, have been named "Management Team of The Year" by
Scrip Intelligence at the 9th annual Scrip Awards. The award was announced
last week by Scrip, a leading pharmaceutical industry publication.
"We are honored to have received this prestigious award," said Dr. Schleifer.
"None of this would have been possible without the dedicated efforts of our
entire team and we accept this award on behalf of all the employees of
"Len and I, along with the entire Regeneron organization, are committed to a
shared vision of developing innovative new scientific and technological
approaches that can deliver life-changing medicines to patients," said Dr.
Yancopoulos. "The last few years have been a transformational time for
Regeneron, and we hope to continue our efforts to bring important new
therapies to patients in need."
Award winners were selected by a 15-member panel of leading pharmaceutical
industry executives, consultants, and researchers. More information about the
panel is available at: http://www.scripintelligence.com/awards/judges/. In
addition to the "Management Team of the Year" award, a Phase 2a asthma study
of dupilumab, which is being developed by Regeneron and Sanofi, was named
"Clinical Advance of the Year" by Scrip Intelligence at the Scrip Awards. In
2012, Scrip honored Regeneron as its Biotech Company of the Year.
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, asthma, and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.
Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of
Regeneron, and actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words, and similar
expressions are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs
now underway or planned, including without limitation dupilumab; unforeseen
safety issues resulting from the administration of products and product
candidates in patients, including serious complications or side effects in
connection with the use of Regeneron's product candidates in clinical trials;
the likelihood and timing of possible regulatory approval and commercial
launch of Regeneron's late-stage product candidates; ongoing regulatory
obligations and oversight impacting Regeneron's research and clinical programs
and business; determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to continue to
develop or commercialize Regeneron's products and product candidates;
competing drugs and product candidates that may be superior to Regeneron's
products and product candidates; uncertainty of market acceptance and
commercial success of Regeneron's products and product candidates; the ability
of Regeneron to manufacture and manage supply chains for multiple products and
product candidates; coverage and reimbursement determinations by third-party
payers, including Medicare and Medicaid; unanticipated expenses; the costs of
developing, producing, and selling products; the ability of Regeneron to meet
any of its sales or other financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential for any
license or collaboration agreement, including Regeneron's agreements with
Sanofi and Bayer HealthCare, to be cancelled or terminated without any further
product success; and risks associated with third party intellectual property
and pending or future litigation relating thereto. A more complete
description of these and other material risks can be found in Regeneron's
filings with the United States Securities and Exchange Commission, including
its Form 10-K for the year ended December 31, 2012 and its Form 10-Q for the
quarterly period ended September 30, 2013. The reader is cautioned not to
rely on any forward-looking statements made by Regeneron. Regeneron does not
undertake any obligation to update publicly any forward-looking statement,
including without limitation any financial projection or guidance, whether as
a result of new information, future events, or otherwise.
Media Relations Investor Relations
Peter Dworkin Manisha Narasimhan, Ph.D.
Tel: 1 (914) 847-7640 Tel: 1 (914) 847-5126
SOURCE Regeneron Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.